|
Real-time Estimate
Cboe BZX
21:11:55 02/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 14.22 USD | +0.39% |
|
-0.04% | -18.67% |
Company Valuation: Summit Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,436 | 10,512 | 10,021 | 8,350 | - | - |
| Change | - | 631.97% | -4.67% | -16.67% | - | - |
| Enterprise Value (EV) 1 | 1,436 | 10,512 | 9,493 | 7,883 | 8,152 | 7,928 |
| Change | - | 631.97% | -9.69% | -16.96% | 3.41% | -2.74% |
| P/E | -2.62x | -58.1x | -12.2x | -12.1x | -12.1x | -20.4x |
| PBR | - | - | 20.7x | 41.4x | 419x | 26.1x |
| PEG | - | 0.8x | -0x | 0.6x | 59.37x | 0.5x |
| Capitalization / Revenue | - | - | - | 2,857x | 200x | 20.3x |
| EV / Revenue | - | - | - | 2,697x | 195x | 19.3x |
| EV / EBITDA | - | -96.9x | -11.7x | -13.8x | -14.9x | -25.4x |
| EV / EBIT | - | -58.8x | -11.7x | -11.9x | -11.5x | -17.4x |
| EV / FCF | - | -93.4x | -39.6x | -14.1x | -12.1x | -13.9x |
| FCF Yield | - | -1.07% | -2.52% | -7.1% | -8.25% | -7.21% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.7828 | -0.2452 | -1.066 | -0.8636 | -0.8618 | -0.5136 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 2.923 | 41.7 | 411.2 |
| EBITDA 1 | - | -108.4 | -810.4 | -571.6 | -547 | -311.8 |
| EBIT 1 | - | -178.8 | -810.5 | -663.5 | -711.5 | -455.1 |
| Net income 1 | -486.2 | -175.1 | -799.5 | -689.2 | -728.9 | -440.9 |
| Net Debt 1 | - | - | -528.6 | -467.3 | -198.6 | -422.2 |
| Reference price 2 | 2.05 | 14.25 | 13.00 | 10.47 | 10.47 | 10.47 |
| Nbr of stocks (in thousands) | 700,843 | 737,448 | 771,150 | 797,750 | - | - |
| Announcement Date | 2/20/24 A | 2/24/25 A | 2/23/26 A | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -12.12x | 2697.2x | -13.79x | -.--% | 11.3B | |
| 20.2x | 7.1x | 14.34x | 1.44% | 68.21B | |
| 36.48x | 9.51x | 29x | 0.04% | 64.25B | |
| -74.38x | 14.34x | -69.16x | -.--% | 26.54B | |
| -15.61x | 5.93x | -7.46x | -.--% | 25.61B | |
| 27.16x | 5.09x | 16.92x | -.--% | 19.88B | |
| 49.41x | 18.23x | 36.98x | 0.31% | 17.13B | |
| 1290.27x | 37.31x | 814.28x | -.--% | 14.93B | |
| 17.57x | 5.23x | 12.21x | -.--% | 14.1B | |
| -85.32x | 7.81x | -64.69x | -.--% | 12.45B | |
| Average | 125.37x | 280.78x | 76.86x | 0.18% | 27.44B | |
| Weighted average by Cap. | 76.71x | 121.13x | 47.94x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SMMT Stock
- Valuation Summit Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
